Pharmacokinetics, efficacy and safety of dupilumab administered with prefilled pen devices in patients aged
British Journal of Clinical Pharmacology · 04.11.2026
DOI: 10.1002/bcp.70895 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 04.11.2026. Verfasst von Amy S Paller und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Regeneron Pharmaceuticals Inc., Sanofi, Regeneron Pharmaceuticals.
Abstract (Originalsprache)
Aim
For children with atopic dermatitis (AD), dupilumab is available as a prefilled syringe (PFS) from the age of 6 months and as a prefilled pen (PFP) for patients aged ≥2 years, in 200‐ and 300‐mg devices. This substudy of an ongoing open‐label extension study evaluated the pharmacokinetics, efficacy and safety of switching from a dupilumab PFS device to a PFP device in children aged 2–11 years with AD.
Methods
Patients received 200 mg of dupilumab every 2 weeks (q2w, Cohort 1B) or 300 mg of dupilumab every 4 weeks (q4w, Cohorts 1A and 2B) based on age (2–5 or 6–11 years) and weight (15–
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Division of Dermatology, Ann & Robert H. Lurie Children's Hospital, Chicago, Illinois, USA.
- Department of Pediatrics, Saint Louis University, St. Louis, Missouri, USA.
- Department of Pediatric Dermatology, Cardinal Glennon Children's Hospital, St. Louis, Missouri, USA.
- Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.
- Sanofi, Cambridge, Massachusetts, USA.
ORCID-Profile: Matthew P Kosloski
Förderung
- Regeneron Pharmaceuticals Inc.
- Sanofi
- Regeneron Pharmaceuticals
Zitieren
APA
Paller, A. S., Siegfried, E. C., Bansal, A., Xiao, J., Khokhar, F. A., Van Spall, M., Liu, X., Xu, C., Dubost-Brama, A., & Kosloski, M. P. (2026). Pharmacokinetics, efficacy and safety of dupilumab administered with prefilled pen devices in patients aged. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70895
Vancouver
Paller AS, Siegfried EC, Bansal A, Xiao J, Khokhar FA, Van Spall M, et al. Pharmacokinetics, efficacy and safety of dupilumab administered with prefilled pen devices in patients aged. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70895
BibTeX
@article{Paller2026,
author = {Paller, Amy S and Siegfried, Elaine C and Bansal, Ashish and Xiao, Jing and Khokhar, Faisal A and Van Spall, Michael and Liu, Xia and Xu, Christine and Dubost-Brama, Ariane and Kosloski, Matthew P},
title = {Pharmacokinetics, efficacy and safety of dupilumab administered with prefilled pen devices in patients aged},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70895}
}
EUVIMED